Own Pain Relief Solution Store In Your City | Franchise Sales & Distribution Call us on 8691006638
Therapeutic anticoagulation is critical in managing moderate to high-risk thrombotic conditions. LMWH therapies such as enoxaparin are widely used due to their effectiveness and predictable anticoagulant response.
ENOXABARA® 80 mg is developed by RIHCA and marketed through RAWIACARE, supporting advanced anticoagulation therapy in hospitals, emergency care, and cardiovascular settings — To Share • To Care • To Inspire.
ENOXABARA® 80 mg is used for therapeutic anticoagulation in patients with active thromboembolic conditions such as DVT and pulmonary embolism.
| Specifications Table | |
| Parameter | Details |
| Brand Name | ENOXABARA® |
| Generic Name | Enoxaparin Sodium |
| Arabic Name | إينوكسابارا إينوكسابارين |
| Category | Anticoagulants |
| Therapeutic Area | Low Molecular Weight Heparin (LMWH) |
| Dosage Form | Injection |
| Strength | 80 mg |
| Volume | 0.8 ml |
| Route / Type | Subcutaneous (Anti-Xa) |
| Developed By | RIHCA |
| Platform Name | RAWIACARE / RAWIACARE GLOBAL |
| Treatment of Deep Vein Thrombosis (DVT) |
| Management of Pulmonary Embolism (PE) |
| Therapeutic anticoagulation in high-risk patients |
| Cardiovascular and hospital-based anticoagulant care |
| Emergency and intensive care anticoagulation support |
| It is used for therapeutic anticoagulation in patients with active thromboembolic conditions such as DVT and pulmonary embolism (PE). |
| It inhibits factor Xa activity, preventing clot formation and improving blood circulation. |
| Patients with moderate to high-risk thrombotic conditions requiring therapeutic anticoagulation under medical supervision. |
| Hospitals, ICU units, emergency departments, and cardiovascular care centers. |
Subcutaneous injection.
| 40 mg, 60 mg, 80 mg |
